Surrogacy of tumor response and progression-free survival for overall survival in metastatic breast cancer resistant to both anthracyclines and taxanes-Reference-Cited by-同舟云学术

Surrogacy of tumor response and progression-free survival for overall survival in metastatic breast cancer resistant to both anthracyclines and taxanes

Published:2011-05-03 Issue:6 Volume:16 Page:623-629
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Matsubara Yoshihiro,Sakabayashi Satomi,Nishimura Tsutomu,Ishida Takanori,Ohuchi Noriaki,Teramukai Satoshi,Fukushima Masanori

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-011-0231-5.pdf

Reference22 articles.

1. U.S. Department of Health and Human Services Food and Drug Administration (2007) Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics

2. Ueno NT, Buzdar AU, Singletary SE et al (1997) Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 40:321–329

3. Berg CD, Swain SM (1994) Results of concomitantly administered chemoradiation for locally advanced noninflammatory breast cancer. Semin Radiat Oncol 4:226–235

4. Ishida T, Kiba T, Takeda M et al (2009) Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol 64:361–369

5. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework;Health Technology Assessment;2021-12

2. Clinical significance of post-progression survival in lung cancer;Thoracic Cancer;2017-06-19

3. Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs;Mayo Clinic Proceedings;2016-06

4. Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer;OncoTargets and Therapy;2014-06

5. Time-dependent endpoints as predictors of overall survival in multiple myeloma;BMC Cancer;2013-03-16